Cell & Gene: The Podcast

Erin Harris
  • 4.9 (37)
  • LIFE SCIENCES
  • UPDATED BIWEEKLY
Cell & Gene: The Podcast

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

  1. NOV 7

    Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

    We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies, with a particular focus on the TECELRA trial. The trial led to the FDA approval of Tecelra, marking a significant milestone as the first engineered T-cell therapy for solid tumors. Williams delves i...

    21 min

  2. OCT 24

    Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte

    We love to hear from our listeners. Send us a message.This episode of Cell & Gene: The Podcast was recorded on site during ARM's 2024 Meeting on the Mesa in Phoenix. Tune in to hear Host Erin Harris talk to Miguel Forte, M.D., Ph.D., CEO of Kiji Therapeutics, President of ISCT, and Executive Committee Member of ARM about Kiji's clinical plan and why iPSC-MSC therapy for inflammatory diseases shows great promise. They also cover this year's conference and what to expect during and after th...

    25 min

  3. OCT 10

    Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D.

    We love to hear from our listeners. Send us a message.Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers. They talk through key challenges and opportunities in developing TCR therapies targeting neoantigens as well as the potential benefits of TCR-T therapies for cancer treatment. Linnemann shares his thoughts on t...

    14 min

  4. SEP 25

    Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge

    We love to hear from our listeners. Send us a message.Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market developed to restore vision in retinal diseases like retinitis pigmentosa.Subscribe to the podcast!Apple | Spotify | YouTube

    22 min

  5. SEP 12

    A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino

    We love to hear from our listeners. Send us a message.Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery.Subscribe to the podcast!Apple | Spotify | YouTube

    28 min

  6. AUG 29

    Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

    We love to hear from our listeners. Send us a message.Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL remains a disease that is managed, it is not one that is often cured. In this episode, Host Erin Harris follows up Roberts' article with in-dept...

    25 min

  7. AUG 15

    CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D.

    We love to hear from our listeners. Send us a message.Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program for Drug Development: Guidance for Industry. She also provides a regulatory outlook for CGT developers.Subscribe to the podcast!Apple | Spotify | YouTube

    28 min

  8. AUG 1

    Identifying Drug Development Opportunities for DMD with CureDuchenne

    We love to hear from our listeners. Send us a message.Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene therapies for Duchenne muscular dystrophy (DMD). Miller and Kelly also share their advice and recommendations for companies developing drugs for DMD...

    30 min
See All (90)

4.9
out of 5
37 Ratings

About

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

Information

  • Creator
    Erin Harris
  • Years Active
    2021 - 2024
  • Episodes
    90
  • Rating
    Clean
  • Copyright
    © 2024 Cell & Gene: The Podcast
  • Show Website
    Cell & Gene: The Podcast

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada